Assessment of thymidylate synthase expression in biopsy specimens and corresponding resection specimens of non‐small‐cell lung cancer

摘要: Herpel E, Schnabel P A, Steins M, Dienemann H, Herth F J F, Thomas Schirmacher & Warth A (2012) Histopathology 61, 465–472 Assessment of thymidylate synthase expression in biopsy specimens and corresponding resection non-small-cell lung cancer Aims:  Pemetrexed (Pem) is a potent inhibitor (TS), has shown efficacy the treatment cancer (NSCLC). TS NSCLC may correlate with tumour responses to TS-inhibiting agents. As not homogeneously expressed, our aim was test whether be representative for whole can used therapeutic assessment. Methods results:  We immunohistochemically analysed 100 consecutive NSCLCs. The samples were subgrouped according levels, degree agreement between specimen calculated. expression-based grouping one cut-off criterion (high or low expression) led concordant results specimens. When more than used, significantly different. Conclusions:  Thymidylate levels correspond when robust scoring systems are applied. Further studies needed determine high predictive value, it allow selection patients who will benefit from Pem treatment.